Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Total Current Liabilities (2016 - 2025)

Tvardi Therapeutics' Total Current Liabilities history spans 13 years, with the latest figure at $11.0 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 6.51% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.0 million, a 6.51% increase, with the full-year FY2025 number at $11.0 million, up 6.51% from a year prior.
  • Total Current Liabilities hit $11.0 million in Q4 2025 for Tvardi Therapeutics, roughly flat from $11.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TVRD hit a ceiling of $28.2 million in Q3 2022 and a floor of $1.2 million in Q1 2025.
  • Historically, Total Current Liabilities has averaged $16.5 million across 5 years, with a median of $16.0 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 81.56% in 2022 and later tumbled 92.06% in 2025.
  • Tracing TVRD's Total Current Liabilities over 5 years: stood at $17.6 million in 2021, then soared by 33.16% to $23.5 million in 2022, then increased by 9.1% to $25.6 million in 2023, then crashed by 59.49% to $10.4 million in 2024, then increased by 6.51% to $11.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for TVRD at $11.0 million in Q4 2025, $11.0 million in Q3 2025, and $10.7 million in Q2 2025.